CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Fluocinonide creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01469767
NCT01469767Phase 2Completed
CompareCT.gov

Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

Wake Forest University·interventional·Posted Nov 10, 2011·Updated Sep 7, 2018

In Brief

A Phase 2 clinical trial evaluating Fluocinonide cream for Atopic Dermatitis. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the efficacy of short-term treatment with fluocinonide cream 0.1% (Vanos®) in the treatment of atopic dermatitis (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
CollaboratorsMedicis Pharmaceutical Corporation

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 10, 2011
Enrollment StartFeb 1, 2012
Primary CompletionAug 17, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.6 years ago

Interventions

Fluocinonide creamdrug

Fluocinonide cream 0.1% applied twice daily for 5 days.